Quality of life during lanadelumab treatment in patients with hereditary angioedema: 24-month results from the enable study

被引：0
|
作者：
Saguer, I. Martinez [1 ]
Magerl, M. [2 ,3 ]
Andriotti, T. [4 ]
Botha, J. [5 ]
Agmon-Levin, N. [6 ]
Watt, M. [4 ]
Maurer, M. [3 ,7 ]
机构：
[1] HRZM Hemophilia Ctr Rhein Main, Morfelden Walldorf, Germany
[2] Charite Univ Med Berlin, Inst Allergol, Berlin, Germany
[3] Fraunhofer Inst Translat Med & Pharmacol ITMP, Berlin, Germany
[4] Takeda Dev Ctr Amer Inc, Lexington, KY USA
[5] Takeda Pharmaceut Int AG, Zurich, Switzerland
[6] Tel Hashomer Hosp, Ctr Autoimmune Dis, Sheba Med Ctr, Ramat Gan, Israel
[7] Charite Univ Med Berlin, Inst Allergol, Berlin, Germany
来源：
ALLERGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
000902
引用
收藏
页码：26 / 27
页数：2
相关论文
共 50 条
  • [21] Clinical status course and quality of life: 24-month results from the European schizophrenia outpatients health outcomes (SOHO) study
    Haro, JM
    Novick, D
    Belger, M
    Ratcliffe, M
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S496 - S496
  • [22] Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS)
    Bente L. Langdahl
    Östen Ljunggren
    Claude-Laurent Benhamou
    Fernando Marin
    George Kapetanos
    Tomaz Kocjan
    Eric Lespessailles
    Nicola Napoli
    Tatjana Nikolic
    Helmut Petto
    Thomas Moll
    Erik Lindh
    [J]. Calcified Tissue International, 2016, 99 : 259 - 271
  • [23] Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS)
    Langdahl, Bente L.
    Ljunggren, Osten
    Benhamou, Claude-Laurent
    Marin, Fernando
    Kapetanos, George
    Kocjan, Tomaz
    Lespessailles, Eric
    Napoli, Nicola
    Nikolic, Tatjana
    Petto, Helmut
    Moll, Thomas
    Lindh, Erik
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2016, 99 (03) : 259 - 271
  • [24] A SURVEY TO DETERMINE TREATMENT PREFERENCES AND QUALITY OF LIFE OF PATIENTS WITH HEREDITARY ANGIOEDEMA
    Diwakar, L.
    Richter, A.
    Huissoon, A.
    Jolles, S.
    El-Shanawany, T.
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 143 - 143
  • [25] Direct treatment cost outcomes among patients with medial meniscus deficiency: results from a 24-month surveillance study
    Hershman, Elliott B.
    Jarvis, John L.
    Mick, Travis
    Dushaj, Kristina
    Elsner, Jonathan J.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (03) : 427 - 437
  • [26] OBSERVATIONAL STUDY ON THE TREATMENT, COST AND QUALITY OF LIFE OF SUBJECTS WITH HEREDITARY ANGIOEDEMA
    Bouillet, L.
    Montauban, V
    Finck, K.
    Jeanbat, V
    Bouee, S.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A386 - A386
  • [27] Effect of Lanadelumab on Coagulation Parameters in Patients With Hereditary Angioedema: Findings From The Phase 3 HELP Study
    Schmaier, Alvin H.
    Bauer, Kenneth A.
    Cicardi, Marco
    Hebert, Jacques
    Johnston, Douglas T.
    Busse, Paula J.
    Paes, Kim
    Sexton, Daniel J.
    Kenniston, Jon
    Nurse, Christina
    Zaragoza, Rafael H.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB42 - AB42
  • [28] LONG-TERM SAFETY OF LANADELUMAB IN HEREDITARY ANGIOEDEMA (HAE): INTERIM RESULTS FROM THE HELP OLE STUDY
    Johnston, D.
    Banerji, A.
    Nurse, C.
    Lu, P.
    Aygoren-Pursun, E.
    Kiani-Alikhan, S.
    Soteres, D.
    Lugar, P.
    Zuraw, B.
    Lockey, R.
    Schwartz, L.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S30 - S30
  • [29] Lanadelumab Effectiveness and Safety in Adolescent Patients With Hereditary Angioedema Aged 12 to <18 Years: Pooled Results From the Real-World ENABLE and EMPOWER Studies
    Tachdjian, Raffi
    Banerji, Aleena
    Busse, Paula
    Agmon-Levin, Nancy
    Anderson, John
    Cancian, Mauro
    Spadaro, Giuseppe
    Enciu, Carmen
    Estepan, Daniel Nova
    Khutoryansky, Natalie
    Recke, Andreas
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB78 - AB78
  • [30] Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: results from phase 3 studies
    Craig, Timothy J.
    Zaragoza-Urdaz, Rafael H.
    Li, H. Henry
    Yu, Ming
    Ren, Hong
    Juethner, Salome
    Anderson, John
    [J]. ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2022, 18 (01):
12345